Actelion Pharmaceuticals grants Helsinn worldwide rights to Valchlor/Ledaga.
M2 EQUITYBITES-March 23, 2018-Actelion Pharmaceuticals grants Helsinn worldwide rights to Valchlor/Ledaga
(C)2018 M2 COMMUNICATIONS http://www.m2.com
Switzerland-based Helsinn has agreed to acquire worldwide rights to Valchlor/Ledaga (mechlorethamine/chlormethine), an alkylating agent intended for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma, from Switzerland-based Actelion Pharmaceuticals.
It was reported yesterday that the deal is subject to customary closing conditions, and is expected to be completed in the second quarter of 2018.
The product is the first and only US Food and Drug Administration (FDA) -approved topical formulation of mechlorethamine. The US FDA has granted it orphan drug designation. To date, limited treatment choices are available for those patients who can benefit from Valchlor through the reimbursement by a wide range of public and commercial payers.
The drug, known as Ledaga in EU was approved by the European Commission in March 2017, for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma in adult patients for all stages and was granted orphan drug designation in 2012.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Mar 23, 2018|
|Previous Article:||The US FDA approves Sun Pharma's plaque psoriasis drug Ilumya.|
|Next Article:||Regeneron Pharmaceuticals collaborates with Alnylam Pharmaceuticals.|